This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q91.0 | Special Copayment Reduction: V160 | Re-certification cycle: 5 years |
| B. Synonyms | None |
| C. Adult onset | First onset in adulthood none — Because of the extremely high case fatality around birth, survival to adulthood is rare in the trisomy 18 meiotic nondisjunction form. As a congenital multiple malformation syndrome, the clinical picture is clear at birth or immediately after birth. |
| 1. History | First described by John H. Edwards in 1960. The third most common autosomal trisomy syndrome. |
| 2. Causes | 47,+18 karyotype due to meiotic nondisjunction (95%). Advanced maternal age is the main risk factor. |
| 3. Genetics | 47,XX,+18 or 47,XY,+18. Mostly sporadic. Recurrence risk about 1%. |
| 4. General epidemiology | About 1/3,000–1/6,000 live births. Female predominance (3:1). Correlated with advanced maternal age. |
| 5. Pathophysiology | Meiosis II nondisjunction is the main mechanism. 3 copies of chromosome 18 → gene overexpression → multisystem malformations. |
| 6. Symptoms | Cardiac malformations (95%), brain malformations, renal malformations, growth retardation, abnormal muscle tone, characteristic clenched fists. |
| 7. Signs | Microcephaly, prominent occiput, characteristic hand posture, short digits, low birth weight, heart murmur. |
| 8. Screening | Prenatal ultrasound, maternal serum screening (quad marker), cfDNA (NIPT). Invasive testing recommended in advanced maternal age. |
| 9. Diagnosis | Karyotype analysis (G-banding), FISH, and chromosomal microarray after chorionic villus sampling or amniocentesis. |
| 10. Treatment | No fundamental treatment. Multidisciplinary palliative care; the decision on cardiac surgery is individualized. |
| 11. Prognosis | 1-year survival rate about 5–10%. Median survival about 5–15 days. The mosaic form is relatively better. |
| 12. Prevention | Awareness of advanced maternal age, prenatal screening and diagnosis, genetic counseling, preimplantation genetic testing (PGT-A). |
| 13. References | Edwards JH (1960) and 9 others. |
Trisomy 18 was first described in 1960 by the British geneticist John Hilton Edwards (1928–2007). In a newborn with multiple congenital malformations and severe intellectual disability, Edwards confirmed through chromosome analysis the presence of an extra autosomal copy, that is, a third copy of chromosome 18, and published it in Lancet in 1960. In the same year, Smith (D.W. Smith), Patau (S.E. Patau), and others independently reported similar cases. The disease is later also called Edwards syndrome after its describer.
At first, trisomy 18 and trisomy 13 (Patau syndrome) were not clearly distinguished, but with advances in karyotyping technology in the early 1960s it was established that the two diseases are different chromosomal abnormalities. With the introduction of G-banding in the 1970s, chromosome 18 could be clearly distinguished from other chromosomes, and the classification of the various subtypes (complete, mosaic, and translocation forms) also became established during this period.
With advances in prenatal ultrasound technology after the 1980s, the characteristic ultrasound findings of trisomy 18 (choroid plexus cysts, characteristic hand posture, cardiac malformations, growth retardation, etc.) were systematically described, and maternal serum screening tests (pattern of changes in α-fetoprotein, unconjugated estriol, hCG, and inhibin A) were established as screening indicators. In the 2010s, next-generation sequencing-based cell-free fetal DNA (cfDNA, NIPT) testing was introduced into clinical practice, enabling high-performance prenatal screening for trisomy 18 with a sensitivity of 98% or more.
In Korea, cases of Edwards syndrome began to be reported systematically after the 1960s with the development of domestic clinical genetics. It is currently included in the rare disease Special Copayment Reduction V160, and clinical guidelines on prenatal diagnosis and postnatal multidisciplinary palliative care have been prepared. Worldwide, discussion continues on the natural history of Edwards syndrome, ethical issues in life-prolonging treatment, and the indications for aggressive surgical treatment.
Trisomy 18, together with Down syndrome (trisomy 21) and Patau syndrome (trisomy 13), is one of the three major autosomal trisomy syndromes in which survival to birth occurs. Trisomies of other autosomes (chromosomes 1–12, 14–17, 19–20, etc.) mostly end in early miscarriage. The reason trisomies of chromosomes 18 and 13 can relatively survive to birth is interpreted to be that these chromosomes have a low gene density, so the effect of gene overexpression from the extra copy is relatively small.
The trisomy 18 meiotic nondisjunction form (Q91.0) is a chromosome number abnormality in which three copies of chromosome 18 are present due to meiotic nondisjunction during gamete formation. About 95% of all Edwards syndrome arises by this mechanism, and the rest are the mosaic form (mitotic nondisjunction, Q91.1) or the translocation form (Q91.2).
Meiotic nondisjunction occurs in meiosis I (nondisjunction of homologous chromosomes) or meiosis II (nondisjunction of sister chromatids) during egg or sperm formation. In trisomy 18, molecular genetic studies show that about 90–95% are of maternal origin, and many of these are known to arise from meiosis II nondisjunction. Paternal origin accounts for only 5–10%.
When meiotic nondisjunction occurs, a disomic gamete containing two chromosomes 18 and a nullisomic gamete lacking chromosome 18 are produced. When a disomic egg (or sperm) is fertilized by a normal sperm (or egg), trisomy of chromosome 18 (trisomy 18) forms, and fertilization of a nullisomic gamete produces monosomy of chromosome 18 (monosomy 18). Monosomy 18 is mostly lost before implantation or in early pregnancy.
The most important risk factor is advanced maternal age (AMA). The incidence increases sharply in mothers aged 35 or older, and the increase is even more pronounced at age 40 or older. The mechanism by which the frequency of meiotic nondisjunction rises with advanced maternal age is presumed to be related to oocyte aging. That is, oocytes arrest at prophase I of the first meiotic division during fetal life and are maintained for decades, with meiosis resuming only at ovulation, so the frequency of errors in spindle-kinetochore attachment is understood to increase in cells maintained for a long time.
A risk factor other than maternal age is a history of a previous pregnancy with a chromosome number abnormality, but in nondisjunction trisomy with a standard karyotype, most cases are new (de novo) nondisjunction events unrelated to previous pregnancy history. An association with environmental factors (radiation, chemicals) has been raised in specific situations, but there is no conclusive evidence.
The karyotype of the trisomy 18 meiotic nondisjunction form is 47,XX,+18 (female) or 47,XY,+18 (male). This is complete trisomy, in which three copies of chromosome 18 are present in all cells. This is confirmed by observing three chromosomes 18 on standard G-banding karyotype analysis.
Chromosome 18 is one of the chromosomes with a relatively low gene density in the human genome, with a size of about 76.1 Mb and containing about 280 protein-coding genes. The global increase in gene expression due to the extra copy (gene dosage effect) is the direct cause of multisystem malformations. In particular, overexpression of genes in the 18q11–q12 region is being studied in relation to cardiac malformations and abnormal brain development, but the causal relationship between individual malformations and specific genes has not yet been fully elucidated.
This subtype is sporadic (de novo occurrence) in principle, and the parental karyotypes are overwhelmingly normal. Therefore, the recurrence risk for siblings is theoretically almost the same as the risk in the general population, but clinically it is customary to present the recurrence risk as about 1% or the age-based risk, whichever is higher. This is because germline mosaicism is possible in some cases.
Translocation trisomy can occur when one parent is a carrier of a balanced chromosomal translocation, but this corresponds to Q91.2. In this subtype (Q91.0), the parental karyotypes are normal, so the recurrence risk is low, but with advanced maternal age the age-based risk continues to increase. Therefore, for parents who delivered a child with trisomy 18 in a previous pregnancy, especially when maternal age is high, prenatal genetic diagnosis is actively recommended in the next pregnancy.
Single nucleotide polymorphism (SNP) microarray analysis, a molecular genetic method, can determine the meiotic stage at which nondisjunction occurred (MI vs. MII) and the parental origin. This is used for research purposes, and G-banding karyotype analysis is the standard for clinical decisions.
Trisomy 18 is reported to occur at a frequency of about 1/3,000–1/6,000 live births. However, because the frequency of spontaneous miscarriage during pregnancy is very high, the frequency at conception is much higher than the birth frequency. The frequency of trisomy 18 at 10 weeks of gestation is estimated at about 1/1,000–1/2,000, and loss by spontaneous miscarriage continues as pregnancy progresses. That is, a considerable number of trisomy 18 conceptions are miscarried in early pregnancy (first trimester), and some end in stillbirth.
In sex distribution, girls are born more often than boys at a ratio of about 3:1. This is interpreted as due to a higher frequency of spontaneous miscarriage in boys. In terms of survival after birth as well, the short-term survival rate of girls tends to be somewhat higher than that of boys.
The correlation with maternal age is clear. The incidence is about 1/10,000 in mothers aged 20–24, whereas it increases to about 1/2,000 at age 35, about 1/750 at age 40, and less than 1/300 at age 45 or older. This is similar to the age-specific risk increase pattern of Down syndrome, but the absolute frequency of trisomy 18 is lower than that of Down syndrome.
In Korea, according to Health Insurance Review & Assessment Service (HIRA) data, several dozen cases of Edwards syndrome are registered as rare disease annually. As the prenatal diagnosis rate has improved and NIPT has been introduced, the proportion diagnosed before birth is rising, and the actual number of live births is on a decreasing trend. Worldwide, the frequency of live births differs by country depending on the social, cultural, and religious background that determines whether pregnancy is terminated after prenatal diagnosis.
Children with trisomy 18 are also associated with obstetric complications such as bipartite placenta, polyhydramnios, and fetal growth restriction (FGR). Polyhydramnios is observed in about 30–50% of trisomy 18 pregnancies and is related to reduced fetal swallowing ability.
The pathophysiology of trisomy 18 is the formation of aneuploidy by chromosomal nondisjunction during meiosis. In normal meiosis, homologous chromosome pairs separate in meiosis I and sister chromatids separate in meiosis II, so each gamete has a haploid (n=23) set of chromosomes. If an error in spindle-kinetochore attachment or an abnormality at the sites of homologous recombination occurs in this process, nondisjunction occurs.
According to molecular studies, the main mechanism of chromosome 18 nondisjunction is meiosis II nondisjunction (in cases of maternal origin). The way to distinguish meiosis I nondisjunction from meiosis II nondisjunction is to determine, by SNP pattern analysis of the trisomic chromosomes, whether maternal heterodisomy or isodisomy is present. Meiosis I nondisjunction produces heterodisomic trisomy, and meiosis II nondisjunction produces isodisomic trisomy.
When chromosome 18 is present in three copies, about 280 genes are overexpressed by 50% (gene dosage effect). The various structural malformations of Edwards syndrome are the result of this widespread gene overexpression. In particular, overexpression of genes involved in cardiac development (GATA6, LAMA3, etc.) is proposed to cause congenital heart defects, and overexpression of brain development-related genes to cause nervous system malformations. However, because chromosome 18 contains major developmental regulatory genes, it is still difficult to clearly define the causal relationship between the occurrence of each malformation and specific genes.
The high frequency of early spontaneous miscarriage is because the extra copy of chromosome 18 causes serious impairment of placental development and early embryonic development after implantation. Even after birth, severe malformations such as cardiac malformations, brain malformations, and apnea coexist in combination, so mortality in the first week of life is very high.
As mechanisms by which the frequency of nondisjunction increases with advanced maternal age, premature separation of chromatids due to reduced cohesin protein in oocytes and reduced function of the spindle assembly checkpoint have been proposed, and these are also commonly observed in Down syndrome and other trisomies.
Trisomy 18 (Edwards syndrome) is characterized by multiple congenital malformations and severe developmental delay. The clinical picture varies, but certain clinical features are observed at high frequency.
Cardiovascular malformations are the most common and clinically important malformations, observed in about 90–95% of affected children. Ventricular septal defect (VSD), patent ductus arteriosus (PDA), atrial septal defect (ASD), polyvalvular disease, and double outlet right ventricle (DORV) are common. Multiple dysplastic valves, described as polyvalvular disease, are relatively characteristic. The severity and type of cardiac malformation are the main factors affecting survival time.
Central nervous system malformations: Microcephaly, agenesis of the corpus callosum, cerebellar hypoplasia, Dandy-Walker malformation, and cortical abnormalities occur in various combinations. Severe intellectual disability and developmental delay are present in all surviving children.
Characteristic limb malformations: The characteristic overlapping posture of the fingers (overlapping fingers, index over middle finger, 5th finger overlapping 4th finger) is very characteristic and is observed in about 90%. Brachydactyly, finger flexion contracture, a short big toe, and rocker-bottom feet or clubfoot also commonly accompany.
Gastrointestinal malformations: Esophageal atresia, intestinal atresia, hernias (inguinal/umbilical hernia), Meckel diverticulum, etc. occur. Dysphagia is present in almost all surviving children, and tube feeding is needed.
Genitourinary malformations: Renal malformations (unilateral renal agenesis, horseshoe kidney), hydronephrosis, and ureteral abnormalities are observed in about 50%. Cryptorchidism is common in boys.
Respiratory problems: From early after birth, respiratory failure and recurrent apneic episodes are major causes of death. Abnormal lung development may also accompany.
The physical examination findings of Edwards syndrome vary, but the following characteristic physical signs suggest the diagnosis.
Craniofacial findings: Microcephaly, a prominent occiput, a narrow low forehead, a small face, microphthalmia or hypertelorism, short palpebral fissures, ptosis, microstomia, a high arched palate or cleft palate, and small low-set ears with malformed external ears are seen. A short sternum is characteristically observed.
Limb signs: The characteristic hand posture mentioned above (overlapping fingers, with the index finger over the middle finger and the little finger over the ring finger) is very characteristic. Rocker-bottom feet or clubfoot deformity are common in the feet. A short big toe and limb shortening are observed.
Skin and physique signs: Low birth weight is typical. Decreased skin tension, limited subcutaneous fat, and a tendency toward short stature are present. Skin defects (cutis aplasia) may rarely accompany.
Cardiac signs: A heart murmur is observed on auscultation, and cyanosis or signs of heart failure (tachypnea, hepatomegaly, edema) appear depending on the cardiac malformation.
Neurological signs: Hypotonia is common in the neonatal period, and excessive hypertonia may also appear in some infants. The sucking reflex and swallowing reflex are weak or absent. Seizures may occur in surviving infants.
Prenatal ultrasound findings: Choroid plexus cysts (CPC), cardiac malformations, growth retardation, polyhydramnios, characteristic hand posture (clenched fists), rocker-bottom feet, single umbilical artery, and cerebellar abnormalities are known as prenatal ultrasound findings of trisomy 18. Choroid plexus cysts alone have low specificity, but when accompanied by other structural abnormalities they greatly increase the risk of trisomy 18.
Prenatal screening tests for Edwards syndrome are performed in an integrated manner together with Down syndrome screening and are also treated as important in Korean prenatal care guidelines.
Maternal serum screening (MSS): The quad marker test performed at 15–20 weeks of gestation (mainly 16–18 weeks) measures α-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG), and inhibin A. In trisomy 18, AFP, uE3, hCG, and inhibin A are all markedly decreased, a characteristic pattern. This is a pattern distinct from Down syndrome (AFP↓, hCG↑, uE3↓, inhibin A↑). The detection rate of quad marker screening for trisomy 18 is about 60–80% (false-positive rate 0.5–1.0%).
First-trimester screening: At 11–14 weeks of gestation, ultrasound measurement of fetal nuchal translucency (NT) is combined with measurement of maternal serum pregnancy-associated plasma protein A (PAPP-A) and free β-hCG. In trisomy 18, increased NT, markedly decreased PAPP-A, and decreased β-hCG are characteristically seen. The detection rate of combined first-trimester screening is about 85–90%.
Cell-free fetal DNA (cfDNA, NIPT): Noninvasive prenatal testing (NIPT), which analyzes placenta-derived cfDNA in maternal blood after 10 weeks of gestation, shows high performance for trisomy 18, with sensitivity of 97–99% and specificity above 99%. The positive predictive value varies with the pretest risk, so a positive result must be confirmed by invasive testing. In Korean guidelines, NIPT is preferentially recommended for high-risk groups (advanced maternal age, high-risk screening, history of a previous trisomy pregnancy), and may be performed selectively in low-risk groups as well.
Prenatal ultrasound: When structural abnormalities are found on detailed ultrasound (detailed standard anatomical examination) at 18–20 weeks of gestation, chromosomal abnormalities including trisomy 18 are included in the differential diagnosis. In particular, choroid plexus cysts accompanied by other structural abnormalities are an indication for aggressive invasive testing.
Confirmation of trisomy 18 (Q91.0) is made by cytogenetic or molecular genetic testing that directly confirms the chromosome number abnormality.
Standard karyotype analysis (G-banding karyotype, conventional karyotype): Prenatally, fetal cells are obtained by chorionic villus sampling (CVS, 11–14 weeks of gestation) or amniocentesis (15–20 weeks of gestation), and G-banding karyotype analysis is performed after cell culture. After birth, confirmation is made by peripheral blood lymphocyte karyotype analysis. Standard karyotype analysis can distinguish complete trisomy 47,+18, the mosaic form (46/47 mixture), and the translocation form. In complete trisomy (Q91.0), three copies of chromosome 18 are observed in all cells.
FISH (Fluorescence in situ hybridization): FISH using a chromosome 18-specific probe can confirm the trisomy rapidly (48–72 hours), and is used in prenatal diagnosis to provide preliminary results while awaiting the standard karyotype result. However, FISH cannot detect translocation forms or structural abnormalities, so it cannot replace standard karyotype analysis.
Chromosomal microarray (CMA): A high-resolution SNP microarray or comparative genomic hybridization (CGH) array can simultaneously detect additional microdeletions/microduplications along with trisomy of chromosome 18. In particular, when structural malformations accompany, confirming additional genomic abnormalities by CMA helps in prognostic assessment.
Next-generation sequencing (NGS)-based methods: The trisomy is confirmed by low-coverage whole-genome sequencing (low-pass WGS) or CMA. A positive prenatal cfDNA (NIPT) result must be confirmed by invasive testing before clinical decisions are made.
Distinguishing the complete form (Q91.0), mosaic form (Q91.1), and translocation form (Q91.2) by karyotype analysis is important for prognostic prediction and recurrence risk counseling. When the translocation form is confirmed, parental karyotype analysis is essential.
There is currently no fundamental treatment for Edwards syndrome. The goal of treatment is to provide the best palliative supportive care and to decide treatment goals suited to the individual child's situation through thorough discussion with the family.
Forming a multidisciplinary team: A multidisciplinary team (MDT) including neonatology, cardiology, neurology, surgery, genetics, palliative care, social work, and psychological support is organized to establish an individualized treatment plan. Thorough communication with the family and shared decision-making are key.
Treatment of cardiac malformations: The indications for and benefits of cardiac surgery are controversial. Some studies report that cardiac surgery in selected children prolongs survival and improves quality of life. However, an individualized approach is needed that comprehensively considers the risks of surgery, life expectancy, and neurological prognosis. Recently, in Japan and some medical institutions, aggressive cardiac surgery has been performed in children with Edwards syndrome, with reports of improved survival beyond 1 year.
Nutritional support: Because of dysphagia, most surviving newborns need tube feeding (nasogastric tube or gastrostomy). Gastrostomy is considered in long-term surviving children.
Respiratory support: For apneic episodes, caffeine therapy, continuous positive airway pressure (CPAP), and whether to use mechanical ventilation are decided after thorough discussion with the family.
Developmental support and rehabilitation: In long-term surviving children (mainly the mosaic form, or the complete form in fortunate survivors), development is supported as much as possible through physical therapy, occupational therapy, and speech therapy.
Palliative care and hospice: When parents choose palliative care, pain and discomfort are minimized, and support is given so that the child can spend the end of life at home or in an environment together with the family.
The overall prognosis of the trisomy 18 meiotic nondisjunction form is very poor. The median postnatal survival is about 5–15 days, the 1-month survival rate is about 30–40%, and the 1-year survival rate is about 5–10%. Some literature reports long-term survival cases (10 years or more), but these are very rare and are mostly mosaic forms or cases with mild malformations.
The main causes of death are heart failure, respiratory failure, apnea, pneumonia, and sepsis. The severity of cardiac malformations is the single most important factor determining survival time.
In surviving children, severe intellectual disability, developmental delay, seizures, growth failure, and recurrent respiratory infections remain persistent problems. Language development is extremely limited, but there are also reports that nonverbal communication and sensory responses are observed in some long-term surviving children, allowing meaningful interaction with the family.
There are increasing reports that the 1-year survival rate improves to 30–50% in children with Edwards syndrome who received aggressive treatment (cardiac surgery, etc.), but long-term data on neurological outcomes and quality of life are still limited. Accordingly, the intensity of treatment for each child should be individualized through thorough information sharing and shared decision-making between the medical team and the family.
In prognostic comparison with the mosaic form (Q91.1), the complete meiotic nondisjunction form (Q91.0) generally shows a worse prognosis. This is because the proportion of abnormal cells in the complete form is 100%, so the effect of gene overexpression operates in all cells.
There is currently no way to prevent the occurrence of trisomy 18 at its source, but affected pregnancies can be identified early through prenatal screening and diagnosis. The main approaches related to prevention are as follows.
Active prenatal screening for advanced maternal age: Because the risk of trisomies including Edwards syndrome increases in mothers aged 35 or older, NIPT or invasive prenatal diagnosis (amniocentesis, CVS) is actively recommended. Because pregnancies at advanced maternal age are themselves increasing worldwide, the absolute number of cases of Edwards syndrome may increase.
Optimizing the prenatal screening program: The detection rate of integrated first- and second-trimester screening is increased, and a screening pathway that uses NIPT cost-effectively is established. When prenatal screening is positive, genetic counseling is provided so that the family can make decisions based on accurate information.
Preimplantation genetic testing (PGT-A, preimplantation genetic testing for aneuploidies): In women of advanced age undergoing assisted reproduction (IVF-ET) or with a history of recurrent miscarriage, implantation of trisomy 18 embryos can be prevented through embryo karyotype analysis (PGT-A). However, cost and ethical considerations are required.
Genetic counseling: After delivery of a child with Edwards syndrome, genetic counseling before the next pregnancy explains the recurrence risk (about 1% or the age-based risk, whichever is higher) and presents prenatal diagnosis options. It is thoroughly explained that the recurrence risk is low in the meiotic nondisjunction form, in which the parental karyotypes are normal.